Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML
Autor: | Beate Betz, Corinna Strupp, Norbert Gattermann, Barbara Hildebrandt, Tobias Schroeder, Martina Rudelius, Esther Schuler, Ulrich Germing, Rainer Haas, Carlo Aul, F. Frank |
---|---|
Rok vydání: | 2017 |
Předmět: |
Neuroblastoma RAS viral oncogene homolog
Male Cancer Research Myeloid Group A Monocytes chemistry.chemical_compound 0302 clinical medicine Mutation Rate Bone Marrow hemic and lymphatic diseases Platelet Aged 80 and over education.field_of_study Serine-Arginine Splicing Factors Esterases Nuclear Proteins Leukemia Myelomonocytic Chronic Hematology Middle Aged Prognosis DNA-Binding Proteins medicine.anatomical_structure Oncology RUNX1 030220 oncology & carcinogenesis Core Binding Factor Alpha 2 Subunit Female Adult Population Dioxygenases 03 medical and health sciences Monocytosis Proto-Oncogene Proteins medicine Biomarkers Tumor Humans Genetic Testing education Aged Cell Proliferation business.industry Myelodysplastic syndromes medicine.disease Repressor Proteins Genes ras chemistry Myelodysplastic Syndromes Immunology Mutation business Carrier Proteins 030215 immunology |
Zdroj: | Leukemia research. 65 |
ISSN: | 1873-5835 |
Popis: | MDS patients may present with monocytic marrow proliferation not fulfilling criteria for CMML. We analyzed MDS patients with or without a marrow monocytic proliferation by following up the amount of monocytic proliferation and characterizing their molecular profile. 315 MDS patients of Duesseldorf MDS registry were divided into two groups: A) 183 patients with monocytic esterase positive cells in marrow and monocytes between 101 and 900/μl in blood and B) 132 patients without monocytic esterase positive cells in marrow and monocytes in blood ≤100/μl. Twenty patients of each group were screened with regard to ASXL1, TET2, RUNX1, SETBP1, NRAS, and SRSF2 using Illumina myeloid panel. Group A patients were older, had significantly higher WBC, hemoglobin levels, neutrophils and platelets. CMML evolution rates were 4.9% and 1.5%, respectively (p = n.s.). TET2, NRAS and SRFS2 mutation frequencies were higher in group A and four patients had coexisting TET2 and SRFS2 mutation, which was shown to be characteristic but not specific for CMML. MDS patients with marrow monocytic proliferation have a more CMML-like pheno- and genotype and develop CMML more often. Those patients could potentially be very early stages of CMML or represent a CMML-like myeloid neoplasma with marrow adherence of the monocytic cell population. |
Databáze: | OpenAIRE |
Externí odkaz: |